Skip to content

A clinical trial to evaluate the short-term efficacy of 650nm wavelength of Ellise on non specific chronic low back pain

A randomized, patient-blinded, placebo-controlled, prospective multi-center confirmative clinical trial to evaluate the safety and short-term efficacy of 650nm wavelength invasive laser medical device (Ellise) on non specific chronic low back pain

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CRIS
Registry ID
KCT0007167
Enrollment
106
Registered
2022-04-08
Start date
2022-05-18
Completion date
Unknown
Last updated
2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Medical Device : The control group will receive sham invasive laser acupuncture(ILA) for 10 min at bilateral acupoints of BL23, BL24, BL25, GB30. 650 nm laser group will receive ILA(power output 20?,

Sponsors

WONTECH
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Participants who meet all of the following criteria will be included in this trial: 1) aged between 19 and 70 years 2) has NSCLBP lasting for at least the preceding three months and has occurred on at least 14 days of each of the preceding 3 months 3) has no change in history of medications for 4 weeks before screening. For participants with medications prescribed and used for NSCLBP, usage shall be at a stable dose in the 4 weeks prior to the screening visit 4) has moderate pain ( 100mm VAS scores for pain was 35-74) at the time of screening 5) has adequate level of Korean language proficiency for the reliable completion of all study assessments 6) voluntarily provides informed consent.

Exclusion criteria

Exclusion criteria: The exclusion criteria are as follows: 1) radicular pain or progressive neurological deficits 2) diagnosis of a serious spinal pathology (cancer, recent vertebral fracture, spinal infection, inflammatory spondylitis, or cauda equina syndrome) 3) presence of a serious chronic disease (cancer, severe cardiovascular, cerebrovascular, liver, kidney disease, or diabetic neuropathy) 4) history of treatment for alcohol/drug dependency or mental illness (schizophrenia, dementia, epilepsy, or depression) in the 6 months preceding enrollment 5) LBP caused by trauma, ankylosing spondylitis, fibromyalgia, rheumatoid arthritis, or gout 6) presence of contradictions for LA , such as blood clotting abnormalities (hemophilia), severe skin disease in the lumbar region, presence of metallic devices in the lumbar spine, or presence of electronic medical devices (pacemaker) 7) moderate or severe depression (scored = 23 points on a Korean version of Beck depression inventory-? ) at the time of screening 8) previous lumbar spinal surgery within a year or scheduled procedures during the study 9) pregnancy or planning to become pregnant 10) concurrent participation in other clinical trials 11) for the purpose of social insurance or compensation 12) not suitable for ILA and our rescue regimen

Design outcomes

Primary

MeasureTime frame
Responder Rate of low back pain with no increase in pain medications

Secondary

MeasureTime frame
Visual Analogue Scale;Oswestry Disability Index;European Quality of Life Five Dimension. Five Level Scale

Countries

Korea, Republic of

Contacts

Public ContactJaeHong Kim

Dongshin University

nahonga@hanmail.net+82-62-350-7209

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 10, 2026